Loading
Life sciences · Journal article
Medicina · October 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background and Objectives: Obesity is a chronic, low-grade inflammatory state. Oxidative stress and reactive oxygen species (ROS) are increasingly recognized as not just passive byproducts but also signaling contributors to metabolic dysfunction in obesity. Among the inflammatory effectors that interact with ROS, the NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome has emerged as an important node linking metabolic stress to interleukin (IL)-1β/IL-18-mediated inflammation and insulin resistance. This review critically examines the ROS–NLRP3 axis as a mechanistic framework for obesity progression, weighing supporting against contradictory evidence and defining translational opportunities. Materials and Methods: A narrative concept-driven review was conducted by searching PubMed, Scopus, and Web of Science throughout August 2026, prioritizing mechanistic, human, and interventional studies of ROS, mitochondrial ROS (mtROS), NLRP3 activation, and obesity, with deliberate inclusion of discordant findings. Results: ROS-dependent NF-κB signaling contributes to NLRP3 priming, whereas mtROS, oxidized mitochondrial DNA, and thioredoxin-interacting protein (TXNIP) are consistently implicated in NLRP3 activation and caspase-1-dependent maturation of IL-1β and IL-18, which are associated with adipose tissue inflammation and impaired insulin signaling. However, loss-of-function studies have yielded inconsistent metabolic protection; human evidence is largely observational, and NLRP3 inhibitors, such as MCC950, carry organ-specific toxicities, indicating context dependence rather than a simple linear pathway. Upstream (mitochondria-targeted antioxidants, TXNIP blockade), core (selective NLRP3 inhibitors), and downstream (IL-1β/IL-18 blockade) strategies are supported mainly by preclinical or early clinical data; for metformin, SGLT2 inhibitors, and GLP-1 receptor agonists, ROS/NLRP3 modulation is a potentially relevant contributory mechanism. Conclusions: The ROS–NLRP3 axis provides a useful mechanistic framework for obesity-associated inflammation, but human causal evidence is limited, and its contribution is tissue-, stage-, and context-dependent; therefore, human-validated, mechanism-based studies are needed.